Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457612 | 0.77 | CHRM2 (0.43) | TSHRKMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL2457323 | 0.77 | CHRM2 (0.43) | TSHRKMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL17056955 | 0.77 | CHRM2 (0.43) | TSHRKMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL2457318 | 0.77 | CHRM2 (0.43) | TSHRKMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL13723301 | 0.70 | CYP3A4 (0.41) | TSHRKMT2AUSP2CYP3A4ALDH1A1 | |
| SCHEMBL13723264 | 0.70 | CYP3A4 (0.33) | USP2CYP3A4ALDH1A1 | |
| SCHEMBL35210215 | 0.68 | ALDH1A1 (0.36) | TSHRKMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL11161495 | 0.67 | TSHR (0.37) | TSHRCYP3A4ALOX15 | |
| SCHEMBL112071 | 0.67 | ALDH1A1 (0.55) | TSHRKMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL273013 | 0.67 | ALDH1A1 (0.55) | TSHRKMT2ACHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579016-B2 | Methods for repelling arthropods using isolongifolenone analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090018192-A1 | Methods for Repelling Arthropods Using Isolongifolenone Analogs | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018192-A1 | Methods for Repelling Arthropods Using Isolongifolenone Analogs | NISCH, CYP51A1, OR51E2 | TSHR 3759/4885KMT2A 3960/4885CHRM2 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.